story of the week
Hyperprogressive Disease in Advanced NSCLC Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
JAMA Oncol 2018 Sep 06;[EPub Ahead of Print], R Ferrara, L Mezquita, M Texier, J Lahmar, C Audigier-Valette, L Tessonnier, J Mazieres, G Zalcman, S Brosseau, S Le Moulec, L Leroy, B Duchemann, C Lefebvre, R Veillon, V Westeel, S Koscielny, S Champiat, C Ferté, D Planchard, J Remon, ME Boucher, A Gazzah, J Adam, E Bria, G Tortora, JC Soria, B Besse, C CaramellaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.